China Shenghuo completes Ph II trial of Wei Dingkang

China Shenghuo Pharmaceutical Holdings, a specialty drug firm engaged in researching, developing, manufacturing and marketing Sanchi-based medicinal products in the People's Republic of China, has announced the completion of testing during Phase II clinical trials for its Wei Dingkang Soft Capsules.

"The completion of Phase II testing is a significant milestone in the development of this important new drug," said Gui Hua Lan, chief executive of the firm. "We expect Wei Dingkang Soft Capsules will be a profit driver in the near future, and we seek to bring a growing number of products to market in the coming months," he added.

Wei Dingkang Soft Capsules use traditional Chinese medicine techniques to treat peptic ulcer disease by inhibiting Helicobacter pylori growth, relieving stomach muscle spasms and reducing inflammation of intestinal lining. The product is a National Type V innovative drug and has been designated as a Major Science and Technology Project in Yunnan Province.